Newly Approved OTC Eye Drop Could Boost Valeant Turnaround Outlook
This article was originally published in The Pink Sheet
Executive Summary
Valeant's Bausch + Lomb subsidiary will have market exclusivity for Lumify, the first OTC brimonidine eye drop. It likely will provide a needed revenue boost as the parent firm navigates a turnaround after incurring more than $30bn debt during the turbulent period under previous management.
You may also be interested in...
Alcaftadine Eye Drops For Allergies Available OTC In US With Allergan’s Lastacaft Launch
Abbvie business starts sales of Lastacaft (alcaftadine solution/0.25%) eye drops, licensed from innovator Vistakon Pharmaceuticals, approved through an sNDA. Full switch removes Lastacaft from Rx sales in US.
Bausch Shines Planned Spin-Out, Launches First US Preservative-Free OTC Antihistamine Eye Drops
Bausch + Lomb’s Alaway Preservative-Free antihistamine eye drops launch in US, The Bausch Health Companies division planned as spin-out also recently gained South Korean approval for its Lumify OTC redness reliever drops and has submissions under review in other countries.
Bausch Considers Proposal For COVID-19 Drug: Lumify Eye Drops Inactivate Virus In Lab Tests
Bausch Health says its Lumify OTC redness reliever drops showed "complete inactivation" of COVID-19 in time-kill tests, with preservative compound benzalkonium chloride apparently the key reason. The in vitro findings prompted it to consider discussions with regulatory agencies on proposing a remedy for the virus.